Business
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients\n - Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and CEO to Executive Chairman and Dr. Mark Erlander will assume the role of CEO\n - Changes mark an important milestone in the Company's evolution and advancing development of onvansertib in cancer indications with the greatest medical need\n\n\nSAN DIEGO, May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and relapsed/refractory leukemias, today announced it is changing its company name to Cardiff Oncology, Inc. and Mark Erlander, PhD, will assume the role of Chief Executive Officer (CEO). In connection with the new corporate name, the Company's Nasdaq ticker symbol will change to 'CRDF' and will be effective at the open of the market on Friday, May 8, 2020. The new website will be https://cardiffoncology.com. \n\n \n \n \n \n \n \n\n \nThe new name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer with its development of onvansertib, a first-in-class, third-generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of cancers representing the greatest need for new effective treatment options.\nDr. Erlander has served as Chief Scientific Officer since joining the Company in 2013 and has been an integral part in its evolution in drug development and biomarker technology. Dr. Thomas Adams, Chairman of the Board since 2009, and CEO since June of 2018, will transition his role to Executive Chairman, and continue to provide his strategic guidance and drug development expertise to the Company.\n\"We are very pleased to announce the change in leadership and company name,\" said Dr. Thomas Adams, Executive Chairman. \"Mark has a proven track record in drug research and development and one of the deepest oncology skills sets in our industry. We believe we are establishing a strong corporate identity with our name change to Cardiff Oncology and demonstrating our expertise and a...